Both CV mortality and major bleeding were rarer when antiplatelets weren’t added, with no tradeoff in ischemic events.

Single-center study finds no thrombosis prevention and more complications ...

Every year, nearly 900,000 Americans are affected by venous thromboembolism (VTE), a condition in which blood clots form in ...

Favorable safety shown in secondary prevention for acute venous thromboembolism ...

Apixaban halved the risk for bleeding compared with rivaroxaban in the treatment of acute venous thromboembolism in the ...

In a study of adults with advanced prostate cancer taking androgen-receptor pathway inhibitors and different types of ...

In patients with atrial fibrillation and a recent stroke history, standard therapy plus catheter ablation did not significantly reduce the risk of the primary composite end point. The observed event ...

In a study of adults with advanced prostate cancer taking androgen-receptor pathway inhibitors and different types of ...

For patients with prostate cancer, concurrent use of enzalutamide, apalutamide, or abiraterone with DOACs does not increase risks for thrombosis or bleeding.

Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing innovative treatments for life-threatening immune and thrombotic conditions, today highlighted recent scientific ...

Apixaban conferred lower bleeding risk during a 3-month period compared with rivaroxaban in patients with acute venous thromboembolism, researchers reported.Despite higher medication adherence to ...

We thank Faizan Khan and Nick van Es, and Zhang Cheng and Yiqi Jin for their Correspondence regarding our post-hoc analysis of the API-CAT trial1,2 in which we identified four non-cancer related, ...